Related Experiment Video
Updated: Feb 20, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
16.3K
Circulating epithelial tumor cells as a prognostic tool for malignant melanoma
Katharina Pachmann1, Regina Willecke-Hochmuth1, Katrin Schneider2
1Labor Dr Pachmann, Bayreuth.
Melanoma Research
|October 28, 2017
Summary
Quantifying circulating tumor cells (CTCs) during interferon therapy can predict melanoma relapse risk. Increasing CTCs indicate a higher risk, while decreasing or stable CTCs suggest a better prognosis.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Interferon-α is a standard therapy for nonmetastatic melanoma, but its relapse prevention efficacy is limited.
- Predictive tools are needed to personalize melanoma treatment and improve outcomes.
- Circulating epithelial tumor cells (CETCs) have emerged as potential biomarkers for metastatic relapse risk.
Purpose of the Study:
- To investigate the utility of quantifying circulating tumor cells (CETCs) as a prognostic marker in malignant melanoma patients undergoing interferon therapy.
- To determine if CETC behavior during treatment correlates with relapse risk.
Main Methods:
- Quantification of CETCs in 49 melanoma patients during interferon treatment.
- Categorization of patients into groups based on increasing or decreasing CETC counts.
- Kaplan-Meier survival analysis to compare outcomes between groups.
Main Results:
- Patients with increasing CETC numbers exhibited a significantly higher risk of relapse.
- A significant difference in survival was observed: mean survival of 2.6 years for increasing CETCs versus 12.6 years for decreasing/stable CETCs (P=0.001).
Conclusions:
- Quantification of CETCs during interferon immunotherapy can serve as a prognostic marker for melanoma patients.
- Further research is warranted to assess CETC applicability in other immunotherapies, such as immune checkpoint inhibitors.
